Agreed. It's interesting how the management team is shifting from an academia background to an industry background. Example, the people from Merck. I think Merck is interested since they didn't have a lot of success with Covid, plus they have people on the inside to validate the drug.
NP doesn't have the quality background to discuss buyout with anyone, so it would have to be Kelly. Plus, NP wants a share of revenue for every indication we have for the drug. I feel that by doing small trials on multiple applications, NP is trying to build value on a buyout stock price. IMO
News 
Market Data 
Discover 
